The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.
Novo moves into amyloidosis not long after Intellia made a splash here.
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.
The Swiss group moves to start a further trial of prasinezumab, but this will not be phase III.
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.
After last year’s flop of Prothena’s NEOD001, Takeda’s Ninlaro fails to treat the underlying cause of the non-genetic form of this disease.
Celgene had many fingers in many pies – so what will happen now to its smaller collaborators?